Neos Therapeutics Inc. (NEOS) Stock Price Down 3.4%
Shares of Neos Therapeutics Inc. (NASDAQ:NEOS) were down 3.4% during trading on Wednesday . The stock traded as low as $6.99 and last traded at $7.08, with a volume of 102,779 shares traded. The stock had previously closed at $7.33.
Several analysts have recently commented on NEOS shares. BMO Capital Markets restated a “buy” rating and issued a $15.00 target price on shares of Neos Therapeutics in a research note on Tuesday, July 19th. Wells Fargo & Co. reiterated a “buy” rating on shares of Neos Therapeutics in a research note on Wednesday, May 18th. Zacks Investment Research cut shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 18th. Finally, Royal Bank Of Canada reduced their price objective on shares of Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating for the company in a research note on Tuesday, May 17th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $21.75.
The company’s 50 day moving average is $8.40 and its 200 day moving average is $9.45. The company’s market capitalization is $113.29 million.
Neos Therapeutics (NASDAQ:NEOS) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.16) by $0.49. The company had revenue of $1.49 million for the quarter, compared to analyst estimates of $1.48 million. On average, equities analysts forecast that Neos Therapeutics Inc. will post ($5.38) EPS for the current fiscal year.
In related news, insider Juergen Martens acquired 10,000 shares of Neos Therapeutics stock in a transaction that occurred on Monday, June 13th. The stock was acquired at an average price of $9.90 per share, with a total value of $99,000.00. Following the completion of the acquisition, the insider now directly owns 10,000 shares of the company’s stock, valued at approximately $99,000. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
A hedge fund recently raised its stake in Neos Therapeutics stock. Marshall Wace LLP increased its stake in Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned approximately 0.60% of Neos Therapeutics worth $1,377,000 at the end of the most recent reporting period.
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).